Alligator Bioscience Secures Pediatric Study Waiver for Mitazalimab

Alligator Bioscience AB ( (SE:ATORX) ) has issued an update.

Alligator Bioscience announced that the European Medicines Agency has granted a waiver for pediatric clinical trials for its lead asset, mitazalimab, in the treatment of pancreatic cancer. This waiver is a significant regulatory milestone, simplifying the path towards potential marketing authorization in the European Union. Mitazalimab, currently in Phase 2 trials, has shown promising results in combination with chemotherapy, significantly improving survival rates for patients with metastatic pancreatic cancer. The waiver allows Alligator to focus on addressing unmet medical needs in adult patients while advancing mitazalimab through late-stage development.

More about Alligator Bioscience AB

Alligator Bioscience is a clinical-stage biotechnology company based in Lund, Sweden, specializing in the development of tumor-directed immuno-oncology antibody drugs targeting the CD40 receptor. The company focuses on enhancing the immune response against tumors, offering potential benefits for cancer patients across various cancer types. Alligator is listed on Nasdaq Stockholm under the ticker ATORX.

Average Trading Volume: 237,832

Current Market Cap: SEK71M

Find detailed analytics on ATORX stock on TipRanks’ Stock Analysis page.